| pubmed-article:18974627 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18974627 | lifeskim:mentions | umls-concept:C0007097 | lld:lifeskim |
| pubmed-article:18974627 | lifeskim:mentions | umls-concept:C0521425 | lld:lifeskim |
| pubmed-article:18974627 | lifeskim:mentions | umls-concept:C0074830 | lld:lifeskim |
| pubmed-article:18974627 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:18974627 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:18974627 | lifeskim:mentions | umls-concept:C0449560 | lld:lifeskim |
| pubmed-article:18974627 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:18974627 | pubmed:dateCreated | 2009-3-2 | lld:pubmed |
| pubmed-article:18974627 | pubmed:abstractText | The majority of gastroenteropancreatic well-differentiated endocrine carcinomas (WDEC) express somatostatin receptors (SSTR). To correlate the expression of SSTR subtypes by reverse transcriptase-polymerase chain reaction (RT-PCR) with clinicopathological features and survival in a group of WDEC patients, 42 WDEC tissue specimens from 33 patients were analysed. All patients were treated with somatostatin analogues and had a median follow-up period of 45 months (range 6-196). Neither SSTR2 and SSTR5 expression nor Ki-67 level alone correlated with survival. A significantly better survival rate was observed in patients with tumours expressing SSTR2, SSTR5 and Ki-67 <2%, compared to those with SSTR2- and SSTR5-negative tumours and Ki-67 >or=2% (p < 0.038), with 5-year survival rates of 91 vs. 43%, respectively. Expression of SSTR2 and SSTR5 appears to play a positive prognostic role, possibly correlated with the high affinity that the available somatostatin analogues display for these 2 specific SSTR subtypes. | lld:pubmed |
| pubmed-article:18974627 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18974627 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18974627 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18974627 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18974627 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18974627 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18974627 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18974627 | pubmed:issn | 1423-0194 | lld:pubmed |
| pubmed-article:18974627 | pubmed:author | pubmed-author:BordiCesareC | lld:pubmed |
| pubmed-article:18974627 | pubmed:author | pubmed-author:FalconiMassim... | lld:pubmed |
| pubmed-article:18974627 | pubmed:author | pubmed-author:ScarpaAldoA | lld:pubmed |
| pubmed-article:18974627 | pubmed:author | pubmed-author:CorletoVito... | lld:pubmed |
| pubmed-article:18974627 | pubmed:author | pubmed-author:Delle... | lld:pubmed |
| pubmed-article:18974627 | pubmed:author | pubmed-author:CannizzaroRen... | lld:pubmed |
| pubmed-article:18974627 | pubmed:author | pubmed-author:MilioneMassim... | lld:pubmed |
| pubmed-article:18974627 | pubmed:author | pubmed-author:PederzoliPaol... | lld:pubmed |
| pubmed-article:18974627 | pubmed:author | pubmed-author:PanzutoFrance... | lld:pubmed |
| pubmed-article:18974627 | pubmed:author | pubmed-author:PerriPasquale... | lld:pubmed |
| pubmed-article:18974627 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:18974627 | pubmed:copyrightInfo | (c) 2008 S. Karger AG, Basel. | lld:pubmed |
| pubmed-article:18974627 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18974627 | pubmed:volume | 89 | lld:pubmed |
| pubmed-article:18974627 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18974627 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18974627 | pubmed:pagination | 223-30 | lld:pubmed |
| pubmed-article:18974627 | pubmed:meshHeading | pubmed-meshheading:18974627... | lld:pubmed |
| pubmed-article:18974627 | pubmed:meshHeading | pubmed-meshheading:18974627... | lld:pubmed |
| pubmed-article:18974627 | pubmed:meshHeading | pubmed-meshheading:18974627... | lld:pubmed |
| pubmed-article:18974627 | pubmed:meshHeading | pubmed-meshheading:18974627... | lld:pubmed |
| pubmed-article:18974627 | pubmed:meshHeading | pubmed-meshheading:18974627... | lld:pubmed |
| pubmed-article:18974627 | pubmed:meshHeading | pubmed-meshheading:18974627... | lld:pubmed |
| pubmed-article:18974627 | pubmed:meshHeading | pubmed-meshheading:18974627... | lld:pubmed |
| pubmed-article:18974627 | pubmed:meshHeading | pubmed-meshheading:18974627... | lld:pubmed |
| pubmed-article:18974627 | pubmed:meshHeading | pubmed-meshheading:18974627... | lld:pubmed |
| pubmed-article:18974627 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:18974627 | pubmed:articleTitle | Somatostatin receptor subtypes 2 and 5 are associated with better survival in well-differentiated endocrine carcinomas. | lld:pubmed |
| pubmed-article:18974627 | pubmed:affiliation | Department of Digestive and Liver Disease, II School of Medicine, University La Sapienza, Roma, Italy. vito.corleto@uniroma1.it | lld:pubmed |
| pubmed-article:18974627 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18974627 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
